In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Synthetic analog Mazdutide | Synthetic analog Semaglutide | |
|---|---|---|---|
| Identity | |||
| Kind | Synthetic analog | Synthetic analog | |
| Area | Weight and metabolic | Weight and metabolic | |
| Evidence | |||
| Amount of evidence | 186 | 4,624 | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 62 (62 in people) | 1,224 (1,221 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | 45 · 25 active | 663 · 284 active124 more mention it but do not test it | |
Shared outcomes
From the regulatory data of each peptide.
No FDA approval and no central EU authorisation (EMA).
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | Mazdutide | Semaglutide |
|---|---|---|
| Body weightMetabolic and weight | 6363 | 969954105 |
| Adverse events |
PepBank is a research reference. Talk to a doctor before you use any peptide.
The FDA label for Ozempic says: “Adjunct to diet and exercise for glycemic control in adults with type 2 diabetes; reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease; reduce the risk of sustained eGFR decline…”
3131 |
7757723 |
| Glycemic controlMetabolic and weight | 2020 | 66866512 |
|---|
| Gastrointestinal adverse eventsGastrointestinal | 3030 | 345345 |
|---|
| Liver fat and liver functionLiver | 9162 | 17917441 |
|---|
| LipidsMetabolic and weight | 9711 | 1181171 |
|---|
| Blood pressureCardiovascular | 33 | 9999 |
|---|
| Appetite and food intakeMetabolic and weight | 22 | 97952 |
|---|
| Inflammation markersLiver | 422 | 51492 |
|---|
| Cardiometabolic risk factorsMetabolic and weight | 33 | 2626 |
|---|
| Cognition and memoryNervous system and cognition | 11 | 1313 |
|---|
| NeuroprotectionNervous system and cognition | 22 | 19109 |
|---|
Each analog against its native parent, residue by residue. Substitutions, non-standard residues and modifications are marked. Calculated from the two sequences.
Mazdutide differs from Oxyntomodulin (human) at 15 positions.
What is different
Semaglutide differs from Glucagon-like peptide 1 (7-37) at 2 positions and carries 1 added group.
What is different
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
| Outcome | Mazdutide | Semaglutide |
|---|---|---|
| Body weightMetabolic and weightCompared as: difference from placebo, in % | −15.15% Between-group difference in body weight Dose studied: 9 mg60 weeksn = 4612026 | −2.54% Body weight change at 13 weeks Dose studied: maximum 14 mg once dailyn = 9,6502026 |
| Glycemic controlMetabolic and weightCompared as: difference from placebo, in % | −1.43% Treatment difference in HbA1c Dose studied: 4 mg24 weeksn not reported2026 | −1.6 to −0.4% Estimated treatment difference Dose studied: 2.5-40 mg once daily26 weeksn not reported2017 |
| Adverse eventsWhole bodyCompared as: value in the arm that got the peptide, in % | 1.5% Discontinuation due to AE · mazdutide 4 mg Placebo: 1% Dose studied: 4 mg once weekly48 weeksn = 6102025 | 16.6% discontinuation due to adverse events Placebo: 8.2% Dose studied: 2.4 mg once weeklyn = 17,6042023 |
| Gastrointestinal adverse eventsGastrointestinalCompared as: share of people in the arm that got the peptide, in % | 46.9% Nausea incidence · mazdutide 9 mg Placebo: 3.2% Dose studied: 9 mg60 weeksn = 4612026 |
−15.15%
Between-group difference in body weight
Dose studied: 9 mg60 weeksn = 4612026
−2.54%
Body weight change at 13 weeks
Dose studied: maximum 14 mg once dailyn = 9,6502026
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | Mazdutide | Semaglutide |
|---|---|---|
| Cardiometabolic risk factorsMetabolic and weightCompared as: value in the arm that got the peptide, in % | No comparable result 3 randomized-trial results measure it in another way or another unit. | −61.1% Relative risk score change Placebo: −12.9% Dose studied: 2.4 mg68 weeks |
43.9%
Nausea incidence · semaglutide 2.4 mg
Dose studied: 2.4 mg once weekly68 weeksn = 3,3792022
−1.43%
Treatment difference in HbA1c
Dose studied: 4 mg24 weeksn not reported2026
−1.6 to −0.4%
Estimated treatment difference
Dose studied: 2.5-40 mg once daily26 weeksn not reported2017
1.5%
Discontinuation due to AE · mazdutide 4 mg
Placebo: 1%
Dose studied: 4 mg once weekly48 weeksn = 6102025
16.6%
discontinuation due to adverse events
Placebo: 8.2%
Dose studied: 2.4 mg once weeklyn = 17,6042023
46.9%
Nausea incidence · mazdutide 9 mg
Placebo: 3.2%
Dose studied: 9 mg60 weeksn = 4612026
43.9%
Nausea incidence · semaglutide 2.4 mg
Dose studied: 2.4 mg once weekly68 weeksn = 3,3792022
| Appetite and food intakeMetabolic and weightCompared as: difference from placebo, in % | No comparable result 2 randomized-trial results measure it in another way or another unit. | 8% Paracetamol AUC0-5h increase Dose studied: 2.4 mg once weekly (dose-escalated)20 weeksn = 722021 |
|---|
| Blood pressureCardiovascularCompared as: difference from placebo, in mm hg | No randomized trial result 3 results from other study designs. | −3.84 mm Hg SBP change at 13 weeks Dose studied: maximum 14 mg once dailyn = 9,6502026 |
|---|
| Inflammation markersImmune and inflammationCompared as: difference from placebo, in % | No randomized trial result 4 results from other study designs. | −18.08% hsCRP change at 13 weeks Dose studied: maximum 14 mg once dailyn = 9,6502026 |
|---|
| LipidsMetabolic and weightCompared as: difference from placebo, in % | No randomized trial result 9 results from other study designs. | −7% Total cholesterol change at 13 weeks Dose studied: maximum 14 mg once dailyn = 9,6502026 |
|---|
| Liver fat and liver functionLiverCompared as: difference from placebo, in percentage points | No randomized trial result 9 results from other study designs. | 28.7 percentage points Estimated difference Dose studied: 2.4 mg once weekly72 weeks (interim analysis; planned 240 weeks)n = 8002025 |
|---|
| NeuroprotectionNervous system and cognitionCompared as: value in the arm that got the peptide, in % | No randomized trial result 2 results from other study designs. | 56.5% Favorable recovery Dose studied: 0.5 mgbefore and 1 week after EVTn = 1402025 |
|---|
| Cognition and memoryNervous system and cognitionCompared as: value in the arm that got the peptide, in z score | No randomized trial result 1 result from other study designs. | 0.32 Z score Adjusted Z score difference Dose studied: 14 mg16 weeksn = 722026 |
|---|
No comparable result
3 randomized-trial results measure it in another way or another unit.
−61.1%
Relative risk score change
Placebo: −12.9%
Dose studied: 2.4 mg68 weeksn = 1,5832023
No comparable result
2 randomized-trial results measure it in another way or another unit.
8%
Paracetamol AUC0-5h increase
Dose studied: 2.4 mg once weekly (dose-escalated)20 weeksn = 722021
No randomized trial result
3 results from other study designs.
−3.84 mm Hg
SBP change at 13 weeks
Dose studied: maximum 14 mg once dailyn = 9,6502026
No randomized trial result
4 results from other study designs.
−18.08%
hsCRP change at 13 weeks
Dose studied: maximum 14 mg once dailyn = 9,6502026
No randomized trial result
9 results from other study designs.
−7%
Total cholesterol change at 13 weeks
Dose studied: maximum 14 mg once dailyn = 9,6502026
No randomized trial result
9 results from other study designs.
28.7 percentage points
Estimated difference
Dose studied: 2.4 mg once weekly72 weeks (interim analysis; planned 240 weeks)n = 8002025
No randomized trial result
2 results from other study designs.
56.5%
Favorable recovery
Dose studied: 0.5 mgbefore and 1 week after EVTn = 1402025
No randomized trial result
1 result from other study designs.
0.32 Z score
Adjusted Z score difference
Dose studied: 14 mg16 weeksn = 722026
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
Top 3 of 45 trials, ranked by phase, then posted results and enrollment: 2 not yet recruiting · 1 completed · source ClinicalTrials.gov (opens in a new tab)
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.912 participantsest. 27 Mar 2026 to est. 31 Dec 2027
Type 2 Diabetes
Huijie Zhang820 participantsest. 1 Sept 2026 to est. 30 Jun 2029
Type 2 Diabetic Kidney Disease
Innovent Biologics (Suzhou) Co. Ltd.731 participants6 Jan 2023 to 9 Apr 2024
Type 2 Diabetes
Top 3 of 663 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Novo Nordisk A/S17,604 participants24 Oct 2018 to 29 Jun 2023
Overweight · Obesity
Novo Nordisk A/S9,651 participants17 Jun 2019 to 23 Aug 2024
Diabetes Mellitus, Type 2
Novo Nordisk A/S3,533 participants17 Jun 2019 to 9 Jan 2024
Diabetes Mellitus, Type 2
124 more mention it but do not test it. They only measure it or name it in their text.